Atrium Therapeutics (RNA) analyst forecast and price target
Analyst forecast
Consensus of 4 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $25.00 | Aug 14, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $25.00 | Aug 6, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $25.00 | Jun 18, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $25.00 | May 15, 2026 |
| HC Wainwright & Co. | — | Neutral | — | May 1, 2026 |
| Wells Fargo | Initiated Coverage | Overweight | $25.00 | Mar 11, 2026 |
Frequently asked questions
Is RNA a buy, sell, or hold?
Analysts covering Atrium Therapeutics currently average a Buy rating: 4 buy, 0 hold and 0 sell, from 4 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on RNA?
On Aug 14, 2026, HC Wainwright & Co. maintained Atrium Therapeutics at Buy with a price target of $25.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.